Clinical Trial Certification: Companies Say IND Submissions Should Be Exempt
Executive Summary
Several companies say FDA is requiring clinical trial sponsors to submit too much trial information to a new public database, and they particularly oppose certification of investigational new drug submissions
You may also be interested in...
ClinicalTrials.gov Requirements Continue To Baffle Firms And Feds Alike
FDA is continuing to solicit questions about the submissions requirements for ClinicalTrials.gov, even though the formal comments deadline on its initial draft guidance has passed
ClinicalTrials.gov Requirements Continue To Baffle Firms And Feds Alike
FDA is continuing to solicit questions about the submissions requirements for ClinicalTrials.gov, even though the formal comments deadline on its initial draft guidance has passed
Clinical Trial Certification Requirements Under FDAAA May Be “Time Bomb”
The section of the FDA Amendments Act that requires companies to post information about their clinical trials contains a "hidden time bomb," according to I. Scott Bass, a partner at the law firm Sidley Austin